Study on the Mechanism of Cognitive Impairment in Patients with Moyamoya Disease

Moyamoya disease (MMD) is a chronic occlusive-stenosis cerebrovascular disease that characterized by the stenosis of internal carotid artery termination and the formation of net-like vessel. It is a multifactorial disease caused by genetic, inflammatory, immunological and other environmental factors. The specific pathogenesis of MMD is still unclear. The treatment modalities of revascularization and conservative management have been used in patients with MMD. Due to the long-term low perfusion state of brain tissue, most patients with MMD experience varying degrees of cognitive dysfunction, although the underlying mechanisms remain unclear. We will employ a combination of 256-lead high-density electroencephalography, multimodal magnetic resonance imaging, and biological samples to conduct a comprehensive evaluation of the risk factors associated with cognitive decline in patients with MMD. Our objectives include identifying target imaging areas indicative of cognitive damage in the brain and exploring the structural and functional changes in the cerebral network resulting from revascularization, as well as their relationship with cognitive improvement.

• Changes in composite score of neurocognitive function at 12 and 24 months after treatment. [Срок оценки: 12 and 24 months during follow-up]
• Rate of participants experiencing cerebrovascular events (TIA, infarction and hemorrhage) within 6, 12 and 24 months after treatment. [Срок оценки: 6, 12 and 24 months during follow-up]
• Changes in neurological function assessed by modified Rankin scale (mRS) at 6, 12, and 24 months following treatment. [Срок оценки: 6, 12 and 24 months during follow-up]
• Changes in neurological function assessed by National Institute of Health stroke scale (NIHSS) at 6, 12, and 24 months following treatment. [Срок оценки: 6, 12 and 24 months during follow-up]
• Changes in cerebral blood perfusion assessed by arterial spin labeling (ASL) at 6, 12, and 24 months after treatment. [Срок оценки: 6, 12 and 24 months during follow-up]
• Hemodynamic changes at the terminal segment of internal carotid artery assessed by computational fluid dynamics (CFD) at 6, 12, and 24 months after treatment. [Срок оценки: 6, 12 and 24 months during follow-up]
• Morphological changes at the terminal segment of internal carotid artery and middle cerebral artery wall assessed by high-resolution vessel wall imaging at 6, 12, and 24 months after treatment. [Срок оценки: 6, 12 and 24 months during follow-up]
• Changes in Power Spectral Density (PSD) assessed by electroencephalography (EEG) at 6, 12, and 24 months after treatment will be measured. [Срок оценки: 6, 12 and 24 months during follow-up]
• Changes in Phase Locking Value (PLV) assessed by electroencephalogram (EEG) at 6, 12, and 24 months after treatment will be measured. [Срок оценки: 6, 12 and 24 months during follow-up]
• Changes in Phase-Lag Index (PLI) assessed by electroencephalogram (EEG) at 6, 12, and 24 months after treatment will be measured. [Срок оценки: 6, 12 and 24 months during follow-up]
• Changes in Degree Centrality assessed by multimodal MRI at 6, 12, and 24 months after treatment. [Срок оценки: 6, 12 and 24 months during follow-up]
• Changes in Clustering Coefficient assessed by multimodal MRI at 6, 12, and 24 months after treatment. [Срок оценки: 6, 12 and 24 months during follow-up]